Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Ying-Nan P. Chen, Nicholas Keen, Matthew J. Meyer(Bristol-Myers Squibb (Germany)), Christine Hiu-Tung Chen, Ping Zhu, François Lenoir, Dyuti Majumdar, Brandon Antonakos, Lawrence Perez, Kang Zhao, Kathy Hsiao, Ji-Hu Zhang, Cary Fridrich, Matthew J. LaMarche(Sanofi (United States)), Jing Yuan(Xiamen University), Denise C. Grünenfelder, Brant Firestone, Zhouliang Chen, Joanna Slisz, Huai-Xiang Hao, Zhan Deng, Michael Acker, Jay F. Larrow, Jaison Jacob, K. Venkatesan(Harvard University), Timothy M. Ramsey, Mitsunori Kato, Edmund V. Price, Peter Fekkes, Rajesh Karki, Samuel B. Ho, Vesselina G. Cooke, Michelle Fodor, Markus Warmuth(Genomics Institute of the Novartis Research Foundation), Minying Pu, Mark Palermo, Subarna Shakya, Laura R. La Bonte, Ping Wang(Xi'an Polytechnic University), Gang Liu(University of Alabama at Birmingham), Hui Gao(Tiangong University), Sarah Williams, Fei Feng, Shumei Liu, Christopher Quinn, Ho Man Chan, Guizhi Yang(Novartis Foundation), Jason R. Dobson, Jorge García‐Fortanet, Michael D. Shultz
Cited by 925
Related Papers
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
|Nature|2012|8.5k
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
|Nature Medicine|2015|1.4k
miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis
|The Journal of Experimental Medicine|2010|931
Network modeling links breast cancer susceptibility and centrosome dysfunction
|Nature Genetics|2007|634